Discovery and characterization of an endogenous CXCR4 antagonist.
Zirafi, O., Kim, K.A., Standker, L., Mohr, K.B., Sauter, D., Heigele, A., Kluge, S.F., Wiercinska, E., Chudziak, D., Richter, R., Moepps, B., Gierschik, P., Vas, V., Geiger, H., Lamla, M., Weil, T., Burster, T., Zgraja, A., Daubeuf, F., Frossard, N., Hachet-Haas, M., Heunisch, F., Reichetzeder, C., Galzi, J.L., Perez-Castells, J., Canales-Mayordomo, A., Jimenez-Barbero, J., Gimenez-Gallego, G., Schneider, M., Shorter, J., Telenti, A., Hocher, B., Forssmann, W.G., Bonig, H., Kirchhoff, F., Munch, J.(2015) Cell Rep 11: 737-747
- PubMed: 25921529 
- DOI: https://doi.org/10.1016/j.celrep.2015.03.061
- Primary Citation of Related Structures:  
2N0X - PubMed Abstract: 
CXCL12-CXCR4 signaling controls multiple physiological processes and its dysregulation is associated with cancers and inflammatory diseases. To discover as-yet-unknown endogenous ligands of CXCR4, we screened a blood-derived peptide library for inhibitors of CXCR4-tropic HIV-1 strains ...